Proto-Oncogene Proteins p21(ras)

"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.

Descriptor ID	D016283
MeSH Number(s)	D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
Concept/Terms	Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) p21 c-ras c-ras, p21 p21 c ras p21(c-ras) ras Proto-Oncogene Protein p21 ras Proto Oncogene Protein p21 Proto-Oncogene Proteins c-ras Proteins c-ras, Proto-Oncogene Proto Oncogene Proteins c ras c-ras, Proto-Oncogene Proteins Proto-Oncogene Protein ras Proto Oncogene Protein ras ras, Proto-Oncogene Protein ras Proto-Oncogene Product p21 ras Proto Oncogene Product p21 c-ras Proteins c ras Proteins p21(ras) Proto-Oncogene Protein p21(ras) Proto-Oncogene Protein p21(c-N-ras) Proto-Oncogene Protein p21(c-N-ras) p21(N-ras) Proto-Oncogene Protein p21(c-Ha-ras) Proto-Oncogene Protein p21(c-Ha-ras) p21 c-Ha-ras c-Ha-ras, p21 p21 c Ha ras p21(c-Ha-ras) p21 c-H-ras c-H-ras, p21 p21 c H ras c-Ha-ras p21 c Ha ras p21 p21, c-Ha-ras Proto-Oncogene Protein p21(c-Ki-ras) Proto-Oncogene Protein p21(c-Ki-ras) p21 c-Ki-ras c-Ki-ras, p21 p21 c Ki ras p21(c-Ki-ras) p21 c-K-ras c-K-ras, p21 p21 c K ras c-Ki-ras p21 c Ki ras p21 p21, c-Ki-ras

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Acid Anhydride Hydrolases [D08.811.277.040]
GTP Phosphohydrolases [D08.811.277.040.330]
GTP-Binding Proteins [D08.811.277.040.330.300]
Monomeric GTP-Binding Proteins [D08.811.277.040.330.300.400]
ras Proteins [D08.811.277.040.330.300.400.500]
Proto-Oncogene Proteins p21(ras) [D08.811.277.040.330.300.400.500.600]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
Monomeric GTP-Binding Proteins [D12.644.360.525]
ras Proteins [D12.644.360.525.500]
Proto-Oncogene Proteins p21(ras) [D12.644.360.525.500.600]
Proteins [D12.776]
Carrier Proteins [D12.776.157]
GTP-Binding Proteins [D12.776.157.325]
Monomeric GTP-Binding Proteins [D12.776.157.325.515]
ras Proteins [D12.776.157.325.515.500]
Proto-Oncogene Proteins p21(ras) [D12.776.157.325.515.500.600]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Monomeric GTP-Binding Proteins [D12.776.476.525]
ras Proteins [D12.776.476.525.500]
Proto-Oncogene Proteins p21(ras) [D12.776.476.525.500.600]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Proto-Oncogene Proteins p21(ras) [D12.776.624.664.700.200]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins p21(ras)".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.

Bar chart showing 62 publications over 24 distinct years, with a maximum of 6 publications in 2011 and 2014 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	0	1	1
2001	0	1	1
2002	0	1	1
2004	1	0	1
2006	0	1	1
2007	2	0	2
2008	2	0	2
2009	1	2	3
2010	0	1	1
2011	2	4	6
2012	2	2	4
2013	0	3	3
2014	2	4	6
2015	4	1	5
2016	2	4	6
2017	1	3	4
2018	1	3	4
2019	2	0	2
2020	2	0	2
2021	1	0	1
2022	0	2	2
2023	1	0	1
2024	1	1	2

Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.

Francis JH, Silverman RF, Canestraro J, Bossert D, Della Rocca D, Hatzoglou V, Abramson DH, Diamond EL. Histiocytosis of the orbit and its association with KRAS mutations. Blood Adv. 2024 10 08; 8(19):5086-5090.

View in: PubMed
Zhu B, Zhu X, Borland MG, Ralph DH, Chiaro CR, Krausz KW, Ntambi JM, Glick AB, Patterson AD, Perdew GH, Gonzalez FJ, Peters JM. Activation of Peroxisome Proliferator-Activated Receptor-?/d (PPAR?/d) in Keratinocytes by Endogenous Fatty Acids. Biomolecules. 2024 May 21; 14(6).

View in: PubMed
Ott CA, Aplin AE. Targeting TEAD-ious resistance. Trends Cancer. 2023 Oct; 9(10):780-781.

View in: PubMed
Wagman LD, Geller DA, Jacobs SA, Petrelli NJ, Allegra CJ, Lipchik C, Pogue-Geile KL, Srinivasan A, Wang Y, O'Connell MJ. NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab. J Surg Oncol. 2022 Dec; 126(8):1494-1503.

View in: PubMed
Gerratana L, Movarek M, Wehbe F, Katam N, Mahalingam D, Donahue J, Shah A, Chae YK, Mulcahy M, Tsarwhas D, Villaflor V, Kalyan A, Hussein M, Patel J, Chandra S, Platanias LC, Gradishar W, Cristofanilli M, Behdad A. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO Precis Oncol. 2022 Jun; 6:e2100289.

View in: PubMed
Rädler PD, Wehde BL, Triplett AA, Shrestha H, Shepherd JH, Pfefferle AD, Rui H, Cardiff RD, Perou CM, Wagner KU. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nat Commun. 2021 06 18; 12(1):3742.

View in: PubMed
Lenkiewicz E, Malasi S, Hogenson TL, Flores LF, Barham W, Phillips WJ, Roesler AS, Chambers KR, Rajbhandari N, Hayashi A, Antal CE, Downes M, Grandgenett PM, Hollingsworth MA, Cridebring D, Xiong Y, Lee JH, Ye Z, Yan H, Hernandez MC, Leiting JL, Evans RM, Ordog T, Truty MJ, Borad MJ, Reya T, Von Hoff DD, Fernandez-Zapico ME, Barrett MT. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. Cancer Res. 2020 10 15; 80(20):4324-4334.

View in: PubMed
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, P?rez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981.

View in: PubMed
Margalit O, Shacham-Shmueli E, Lawrence YR, Yang YX, Reiss KA, Golan T, Mamtani R, Halpern N, Aderka D, Giantonio B, Boursi B. Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. Clin Colorectal Cancer. 2019 09; 18(3):e300-e307.

View in: PubMed
Gripp KW, Morse LA, Axelrad M, Chatfield KC, Chidekel A, Dobyns W, Doyle D, Kerr B, Lin AE, Schwartz DD, Sibbles BJ, Siegel D, Shankar SP, Stevenson DA, Thacker MM, Weaver KN, White SM, Rauen KA. Costello syndrome: Clinical phenotype, genotype, and management guidelines. Am J Med Genet A. 2019 09; 179(9):1725-1744.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement